NCT03226691View on ClinicalTrials.gov

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

February 27, 2019

Study Completion Date

February 27, 2019

Conditions
Sickle Cell Disease
Interventions
DRUG

Plerixafor

Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

St. Jude Children's Research Hospital

OTHER

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03226691 - Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients | Biotech Hunter | Biotech Hunter